BackTable Urology
Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay
Aditya Bagrodia
So, you know, I love the way you mentioned that it's the duration, the intensity, and the kind of intent of therapy that are largely modulating this. And maybe we can start out with, you know, four to six months ADT for generally unfavorable intermediate risk prostate cancer. What agents, any kind of major preference? And maybe I'll just throw this out there.
0
💬
0
Comments
Log in to comment.
There are no comments yet.